Stockscreener 앱 받기
1.35
0.75%
0.01
전일 마감가:
$1.34
열려 있는:
$1.32
하루 거래량:
106.09K
Relative Volume:
0.09
시가총액:
$22.84M
수익:
-
순이익/손실:
$-11.24M
주가수익비율:
-1.7728
EPS:
-0.7615
순현금흐름:
$-4.79M
1주 성능:
+10.66%
1개월 성능:
+20.54%
6개월 성능:
+4.65%
1년 성능:
+68.75%
1일 변동 폭
$1.29
$1.37
1주일 범위
$1.21
$1.43
52주 변동 폭
$0.51
$5.01
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
명칭
Mira Pharmaceuticals Inc
전화
813-369-5150
주소
1200 BRICKELL AVENUE, MIAMI
MIRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.35 | 20.64M | 0 | -11.24M | -4.79M | -0.7615 |
|
LLY
Lilly Eli Co
|
737.67 | 640.72B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.21 | 367.98B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
186.11 | 323.71B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.76 | 222.69B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
71.50 | 299.26B | 43.59B | 15.04B | 10.74B | 3.3766 |
Mira Pharmaceuticals Inc 주식(MIRA)의 최신 뉴스
MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program - Lohud
MIRA Pharmaceuticals (MIRA) Sets Sights on Major Advancements | - GuruFocus
MIRA Pharmaceuticals (MIRA) Sets Sights on Major Advancements | MIRA Stock News - GuruFocus
MIRA Pharmaceuticals Joins BIO Convention for Strategic Opportunities - TipRanks
MIRA's Novel Pain Drug Shows Promise: Phase 1 Success Leads to Phase 2 Plans as Acquisition Nears - Stock Titan
MIRA Pharmaceuticals announces clinical progress and acquisition update - Investing.com
MIRA Pharmaceuticals announces clinical progress and acquisition update By Investing.com - Investing.com Nigeria
MIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60M - MSN
MIRA Pharmaceuticals appoints new CFO - Investing.com Australia
MIRA Pharmaceuticals Appoints New Chief Financial Officer - TipRanks
MIRA Pharmaceuticals appoints new CFO By Investing.com - Investing.com UK
MIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment Strong - MSN
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
MIRA Pharmaceuticals (MIRA) Projected to Post Earnings on Monday - Defense World
Why Mira Pharmaceuticals Inc (NASDAQ: MIRA) Is A Great Stock Pick For Momentum Investors - Stocksregister
MIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment Strong By Stocktwits - Investing.com India
MIRA Pharmaceuticals Acquires SKNY Pharmaceuticals for $60M - TipRanks
MIRA Pharmaceuticals to acquire SKNY in strategic move - Investing.com
MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review - Corsicana Daily Sun
EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million - Benzinga
Renaissance Technologies LLC Takes Position in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) - Defense World
MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity - The Joplin Globe
MIRA Achieves Positive Safety Results in Neurotoxicity Study | M - GuruFocus
EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study - AOL.com
MIRA Pharmaceuticals reports safe profile for Ketamir-2 - Investing.com
MIRA Pharmaceuticals reports safe profile for Ketamir-2 By Investing.com - Investing.com UK
MIRA Pharmaceuticals Completes Key Neurotoxicity Study for Ketamir-2 - TipRanks
Breakthrough: New Drug Outperforms Ketamine in FDA Brain Safety StudyZero Toxicity Detected - Stock Titan
Pharmaceutical Stock Jumps After Key Trial Findings - MSN
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Down 14.1% in April - Defense World
Mira Pharmaceuticals Inc [MIRA] moved up 7.08: Why It’s Important - dbtnews.com
Financial Metrics Unveiled: Mira Pharmaceuticals Inc (MIRA)’s Key Ratios in the Spotlight - DWinneX
MIRA Pharmaceuticals reports positive in vitro drug release data for topical Ketamir-2 - MSN
Mira Pharmaceuticals announces key drug development milestone By Investing.com - Investing.com Canada
Mira Pharmaceuticals announces key drug development milestone - Investing.com Australia
MIRA Pharmaceuticals (MIRA) Advances Ketamir-2 Formulations in P - GuruFocus
MIRA Pharmaceuticals reports positive Ketamir-2 study By Investing.com - Investing.com India
MIRA Pharmaceuticals reports positive Ketamir-2 study - Investing.com
MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation - Weatherford Democrat
Press Release Distribution & PR Platform - ACCESS Newswire
MIRA's Novel Pain Treatment Delivers Positive Data, Targets Massive $11.5B Market With Fast-Track Potential - Stock Titan
Mira Pharmaceuticals Inc (MIRA) is a good investment, but the stock may be undervalued - uspostnews.com
MIRA’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Promising Canadian Stocks To Follow Now – April 16th - Defense World
Mira Pharmaceuticals Inc (MIRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.17%
0.93%
자본화:
|
볼륨(24시간):